State-of-the-Art Lecture: Emerging Toxicities Of Hormonal Therapy

ORLANDO, FL (UroToday.com) - Dr. Matthew Smith of Harvard University addressed toxicities of hormonal therapy. Initiating ADT for men with CaP brings challenges. Many have indolent disease and co-morbid conditions and there is inadequate information about benefits. Initial use of DES was abandoned when the two-fold increase in thromboembolic events were noted. He said we must still assess present GnRH agonists use for any toxicities as well. For most men CaP is indolent.

More: continued here

Filed under: Endocrinology on June 30th, 2008